Skip to main content

ENvue Medical, Inc.

corporate_fare Company Profile

ENvue Medical, Inc.

ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. The company's product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. It also provides UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. It sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. The company was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. ENvue Medical, Inc. was incorporated in 2003 and is based in Tyler, Texas.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed FEED - Latest Insights

FEED
Apr 20, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
FEED
Apr 17, 2026, 4:57 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
FEED
Apr 15, 2026, 5:19 PM EDT
Filing Type: 10-K
Importance Score:
9
FEED
Mar 24, 2026, 8:07 AM EDT
Source: GlobeNewswire
Importance Score:
7
FEED
Feb 11, 2026, 6:52 PM EST
Filing Type: 4
Importance Score:
9
FEED
Feb 11, 2026, 6:22 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
9
FEED
Feb 06, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
9
FEED
Jan 30, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
8